Our objective was to identify the outcome of patients treated with tissue plasminogen activator (r-tPa) in Pakistan and compare these data to available regional and international data. The charts of all patients treated with r-tPa for acute stroke at two centers in Pakistan (Aga Khan University, Karachi and Liaquat National hospital, Karachi) were retrospectively reviewed. We identified 21 patients. The utilization of tPa at Aga Khan Hospital was 18/1,185 patients (1.5%) from 2005 to 2007 while at Liaquat National Hospital was 3/575 patients (0.52%) over 1 year (2007). Mean time interval between stroke onset and start of r-tPa infusion was 169 min. Three patients (14%) developed fatal hemorrhage and two (10%) developed non-fatal hemorrhage....
Objective: To determine the utilisation of intravenous tissue plasminogen activator at a certain dos...
Objective: To determine the utilisation of intravenous tissue plasminogen activator at a certain dos...
Objective: To determine the utilisation of intravenous tissue plasminogen activator at a certain dos...
Our objective was to identify the outcome of Patients treated with tissue plasminogen activator (r-t...
Our objective was to identify the outcome of Patients treated with tissue plasminogen activator (r-t...
Our objective was to identify the outcome of Patients treated with tissue plasminogen activator (r-t...
Our objective was to identify the outcome of Patients treated with tissue plasminogen activator (r-t...
Our objective was to identify the outcome of Patients treated with tissue plasminogen activator (r-t...
Our objective was to identify the outcome of Patients treated with tissue plasminogen activator (r-t...
Our objective was to identify the outcome of Patients treated with tissue plasminogen activator (r-t...
Background: The only accepted treatment for acute ischemic stroke is thrombolysis with recombinant ...
Background: The only accepted treatment for acute ischemic stroke is thrombolysis with recombinant ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Objective: To determine the utilisation of intravenous tissue plasminogen activator at a certain dos...
Objective: To determine the utilisation of intravenous tissue plasminogen activator at a certain dos...
Objective: To determine the utilisation of intravenous tissue plasminogen activator at a certain dos...
Our objective was to identify the outcome of Patients treated with tissue plasminogen activator (r-t...
Our objective was to identify the outcome of Patients treated with tissue plasminogen activator (r-t...
Our objective was to identify the outcome of Patients treated with tissue plasminogen activator (r-t...
Our objective was to identify the outcome of Patients treated with tissue plasminogen activator (r-t...
Our objective was to identify the outcome of Patients treated with tissue plasminogen activator (r-t...
Our objective was to identify the outcome of Patients treated with tissue plasminogen activator (r-t...
Our objective was to identify the outcome of Patients treated with tissue plasminogen activator (r-t...
Background: The only accepted treatment for acute ischemic stroke is thrombolysis with recombinant ...
Background: The only accepted treatment for acute ischemic stroke is thrombolysis with recombinant ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Objective: To determine the utilisation of intravenous tissue plasminogen activator at a certain dos...
Objective: To determine the utilisation of intravenous tissue plasminogen activator at a certain dos...
Objective: To determine the utilisation of intravenous tissue plasminogen activator at a certain dos...